Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Retrieved on:
Tuesday, August 3, 2021
Key Points:
Clinical trials
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
Retrieved on:
Tuesday, August 3, 2021
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates.
Key Points:
- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today reported second quarter 2021 financial results and provided business updates.
- Appointment of Chief Financial Officer and Head of Business Development: In May, Seres announced that David Arkowitz was appointed as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development.
- Research and development expenses for the second quarter of 2021 were $36.0 million, compared with $20.1 million for the same period in 2020.
- General and administrative expenses for the second quarter of 2021 were $17.5 million, compared with $6.5 million for the same period in 2020.
U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration
Retrieved on:
Tuesday, August 3, 2021
Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.
Key Points:
- Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.
- Entitled Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial , this paper describes the treatment effect of risuteganib 1.0 mg in patients with intermediate dry AMD.
- These clinical data suggest that risuteganib can reverse vision loss and restore functional vision in patients with intermediate dry AMD with treatment at a 12-week interval.
- Phase 2a study with risuteganib in less advanced dry AMD met its primary endpoint of vision recovery.
Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology
Retrieved on:
Tuesday, August 3, 2021
Iterative Scopes, a pioneering company aiming to bring cutting-edge precision medicine to gastroenterology, today disclosed that it has closed a $30 million Series A financing.
Key Points:
- Iterative Scopes, a pioneering company aiming to bring cutting-edge precision medicine to gastroenterology, today disclosed that it has closed a $30 million Series A financing.
- For a variety of reasons, gastroenterology has seen fewer benefits from precision medicine tools than other serious illnesses such as oncology and infectious diseases.
- As part of the financing, Nan Li, Managing Director at Obvious Ventures, will also join Iterative Scopes board of directors.
- Iterative Scopes has developed world-class AI capabilities to accelerate the industry towards drastically improved clinical decision-making and ultimately precision medicine.
Worldwide Clinical Trials’ Aman Khera Recognized Among Pharmavoice 100 Most Inspiring People
Retrieved on:
Tuesday, August 3, 2021
Worldwide Clinical Trials , Inc. (Worldwide), the industrys leading global, midsized, full-service contract research organization (CRO), today announced that its Vice President, Global Head of Regulatory Strategy Aman Khera has been recognized as one of the 100 Most Inspiring People in the Life Sciences Industry by PharmaVOICE.
Key Points:
- Worldwide Clinical Trials , Inc. (Worldwide), the industrys leading global, midsized, full-service contract research organization (CRO), today announced that its Vice President, Global Head of Regulatory Strategy Aman Khera has been recognized as one of the 100 Most Inspiring People in the Life Sciences Industry by PharmaVOICE.
- In all that she does, Aman champions the strategic role of regulatory professionals and advocates for diversity, inclusion and belonging in clinical research.
- Amans tireless efforts and pursuit of regulatory excellence have contributed to Worldwides continued growth and success, said Henry Riordan, PhD, Chief Development Officer, Worldwide Clinical Trials.
- Congratulations to Aman Khera and the other 2021 PharmaVOICE 100 honorees, said Peter Benton, President and co-CEO of Worldwide.
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
Retrieved on:
Tuesday, August 3, 2021
In the interim, BeiGene plans to rent space nearby and begin to hire immediately.
Key Points:
- In the interim, BeiGene plans to rent space nearby and begin to hire immediately.
- We are proud to be building our campus in New Jersey, and were grateful for the warm welcome BeiGene has received across the state, said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.
- We are excited to connect more with the deep talent pool in the region as we plan to diversify and further expand.
- We hope that BeiGene and its new manufacturing and R&D campus in Hopewell will help bring that day closer to reality, said New Jersey Governor Phil Murphy.
Personal Genome Diagnostics Appoints Jamie Platt, Ph.D., as Chief Operations Officer
Retrieved on:
Tuesday, August 3, 2021
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer.
Key Points:
- Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer.
- The addition of a Chief Operations Officer to the PGDx management team is an invaluable one as we continue to grow our product roadmap and services offerings, driven by relentless commitment to improving cancer care on a global scale, said Megan Bailey, Chief Executive Officer.
- Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome.
- PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.
Engrail Therapeutics Extends Series A Financing to $64 Million
Retrieved on:
Tuesday, August 3, 2021
Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.
Key Points:
- Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.
- Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
- Engrails lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles that possess wide ranging therapeutic utility.
- Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system.
Veranex Announces Acquisition of Experien Group
Retrieved on:
Tuesday, August 3, 2021
Veranex , the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.
Key Points:
- Veranex , the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.
- We are excited to welcome Experien Group to Veranex, said David Dockhorn , CEO of Veranex.
- With this acquisition, Veranex adds the premier provider of regulatory, quality, and clinical consulting services to medtech companies.
- Experien Group adds another layer of value and medtech insight to Veranex, said Veranex Executive Chairman Pat Donnelly .
Goldfinch Bio to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference
Retrieved on:
Tuesday, August 3, 2021
Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal Part 1 Novel Mechanisms in Renal Disorders, at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 3:30 p.m.
Key Points:
- Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal Part 1 Novel Mechanisms in Renal Disorders, at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 3:30 p.m.
- Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases.
- We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets.
- In 2020, Goldfinch Bio was named one of Fierce Biotechs Fierce 15 companies.